Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Dtsch Med Wochenschr ; 136(37): 1842-4, 2011 Sep.
Article in German | MEDLINE | ID: mdl-21898275

ABSTRACT

UNLABELLED: MEDICAL HISTORY AND CLINICAL FINDINGS: A 70-year-old female patient suffered from steatorrhea and upper abdominal discomfort for 8 weeks combined with new onset of arthralgia in both hands. Additionally she reported elevated fasting blood glucose levels. The physical examination was without pathological findings except for mild upper abdominal pressure pain. INVESTIGATIONS: Imaging studies, including MRI and ultrasound examinations showed diffuse pancreatic enlargement without peripancreatic vessel involvement. Serological examinations showed elevated Cancer Associated Antigen 19 - 9 (1289 U/ml) and hyperglobulinemia with an IgG level of 170 mg/dl. The inflammatory markers were within normal ranges other than a slightly elevated erythrocyte sedimentation rate (35mm/1 h). Subsequent pancreatic biopsy showed lymphoplasmocellular, neutrophile and eosinophile granulocyte infiltration causing damage of the acinar pancreatic cells, typical for autoimmune pancreatitis (AIP). Magnetic resonance imaging (MRI) confirmed arthritis of both hands. TREATMENT AND COURSE: Medical treatment was started with oral prednisolone (50 mg/day) for one week, tapered to 25 mg/day for another 2 weeks, followed by dose reductions of 5 mg/day every 2 weeks with a final maintenance dose of 5 mg/day for 8 months. After the first week of steroid therapy methotrexate (MTX) was started with an initial dose of 10 mg/week. Dose was raised until a final dosage of 30 mg/week. After 8 months without relapse, the maintenance therapy was reduced to 20 mg/week MTX and corticosteroids were stopped. CONCLUSION: With this treatment regimen the patient has showed complete remission of AIP and arthritis for 36 months. MTX may be successful as an initial basic treatment to reach better control of autoimmune-related extrapancreatic manifestations.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Autoimmune Diseases/drug therapy , Immunosuppressive Agents/therapeutic use , Methotrexate/therapeutic use , Pancreatitis/drug therapy , Prednisolone/therapeutic use , Aged , Aged, 80 and over , Anti-Inflammatory Agents/adverse effects , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/pathology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/pathology , Biopsy , Comorbidity , Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Diabetes Mellitus/pathology , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/adverse effects , Magnetic Resonance Imaging , Metacarpophalangeal Joint/pathology , Methotrexate/adverse effects , Pancreas/pathology , Pancreatitis/diagnosis , Pancreatitis/pathology , Prednisolone/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...